title: Esophageal pharmacology and treatment of primary motility disorders.
abstract: Swallowing is a complex mechanism based on the coordinated collaboration of tongue, pharynx and esophagus. Disturbances of this interplay or disorders of one or several of these components lead to dysphagia, non-cardiac chest pain or regurgitation. The major primary esophageal motility disorders--achalasia, diffuse esophageal spasm, hypercontractile esophagus ('nutcracker esophagus') and non-specific motility disorder--are of unknown etiology. Other esophageal diseases, such as cervical diverticula or gastroesophageal reflux disease, might also be caused by a primary esophageal motility disorder. Medical treatment of esophageal disorders with esophageal hyper- or dysmotility requires agents that reduce esophageal contractile force (anticholinergic agents, nitrates, calcium antagonists). Despite the beneficial effect of the various drugs on esophageal motility parameters, the clinical benefit of medical treatment of esophageal motility disorders is rather disappointing. Calcium channel antagonist, alone or in combination with anticholinergics or nitrates, can be used as a medical trial, especially in mild achalasia. However, medical therapy is clearly inferior to pneumatic balloon dilation therapy. Recently, botulinum toxin injection was suggested as a therapeutic option in achalasia patients with good results on lower esophageal sphincter pressure (LESP) and symptom scores that were similar to the results achieved by pneumatic balloon dilation. Hypercontractile esophagus shows a good manometric response to calcium channel antagonists, but only little clinical effect in terms of improvement of symptoms. Diffuse esophageal spasm is a relatively rare disease and few clinical studies are available. The use of calcium channel antagonists can be beneficial, at least in some patients with diffuse esophageal spasm. From clinical and epidemiological studies, there is some evidence of a 'psychological' component in the pathogenesis or perception of esophageal symptoms. There is some clinical benefit from centrally acting drugs such as benzodiazepines or antidepressants. With the exception of botulinum toxin for achalasia, medical therapy of primary esophageal motility disorders is rather limited and the clinical results are poor. Further understanding of esophageal pathophysiology as well as development of new receptor-selective drugs might increase our chances of a successful treatment of primary esophageal motility disorders.
authors.affiliation: Department of Internal Medicine II, Technical University of Munich, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Storr
authors.forename: H D
authors.initials: HD
authors.lastname: Allescher
mesh_terms: D000818:Animals; D001521:Behavior Therapy; D001905:Botulinum Toxins / Q000494:pharmacology; D018678:Cholinergic Agents / Q000494:pharmacology; D002986:Clinical Trials as Topic; D004931:Esophageal Achalasia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D015154:Esophageal Motility Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004947:Esophagus / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D000431:Ethanol / Q000494:pharmacology; D006801:Humans; D009294:Narcotics / Q000494:pharmacology; D011379:Prognosis; D011619:Psychotropic Drugs / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D018678:Cholinergic Agents; D009294:Narcotics; D011619:Psychotropic Drugs; D000431:Ethanol; D001905:Botulinum Toxins